Ticker
ABVC

Price
0.84
Stock movement down
-0.02 (-2.70%)
Company name
ABVC Biopharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
27.23M
Ent value
29.22M
Price/Sales
65.95
Price/Book
3.70
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-67.71%
3 year return
-66.54%
5 year return
-89.86%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ABVC does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales65.95
Price to Book3.70
EV to Sales70.76

FINANCIALS

Per share

Loading...
Per share data
Current share count32.31M
EPS (TTM)-0.81
FCF per share (TTM)-0.35

Income statement

Loading...
Income statement data
Revenue (TTM)412.90K
Gross profit (TTM)405.27K
Operating income (TTM)-16.67M
Net income (TTM)-21.90M
EPS (TTM)-0.81
EPS (1y forward)-0.22

Margins

Loading...
Margins data
Gross margin (TTM)98.15%
Operating margin (TTM)-4037.79%
Profit margin (TTM)-5304.34%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash2.72M
Net receivables3.14M
Total current assets7.99M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets12.07M
Accounts payable0.00
Short/Current long term debt3.17M
Total current liabilities3.66M
Total liabilities4.71M
Shareholder's equity7.36M
Net tangible assets7.43M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-9.18M
Capital expenditures (TTM)281.95K
Free cash flow (TTM)-9.46M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-297.52%
Return on Assets-181.50%
Return on Invested Capital-284.05%
Cash Return on Invested Capital-122.70%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.84
Daily high0.89
Daily low0.83
Daily Volume46K
All-time high716331.21
1y analyst estimate3.00
Beta0.74
EPS (TTM)-0.81
Dividend per share-
Ex-div date-
Next earnings date14 Nov 2022

Downside potential

Loading...
Downside potential data
ABVCS&P500
Current price drop from All-time high-100.00%-13.41%
Highest price drop-100.00%-56.47%
Date of highest drop24 Aug 20229 Mar 2009
Avg drop from high-90.64%-11.38%
Avg time to new high112 days12 days
Max time to new high1616 days1805 days
COMPANY DETAILS
ABVC (ABVC Biopharma Inc) company logo
Marketcap
27.23M
Marketcap category
Small-cap
Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Employees
28
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hemato...
September 23, 2022
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing the...
September 16, 2022
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematol...
September 13, 2022
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical comp...
September 9, 2022
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceuti...
August 22, 2022
Phase II Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical...
August 18, 2022
FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
August 15, 2022
-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
July 18, 2022
FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
July 13, 2022
FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematolog...
July 6, 2022
Next page